European CHMP recommends paediatric license extension of blinatumomab (Blincyto) for acute lymphoblastic leukaemia (ALL)

The proposed license extension is as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy.

Source:

European Medicines Agency